Trial record 6 of 21 for:
sasa
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04707235 |
|
Recruitment Status :
Recruiting
First Posted : January 13, 2021
Last Update Posted : March 25, 2022
|
Sponsor:
ADDMEDICA SASA
Collaborator:
International Clinical Trials Association
Information provided by (Responsible Party):
ADDMEDICA SASA
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
As safety information pertaining to the long-term use of HU remains incomplete in spite of the first safety study (ESCORT-HU), an extension of the latter is proposed. ESCORT-HU Extension study aims at evaluating the long-term safety of Siklos® focusing on some questions regarding its safety when used in current practice in adults and paediatric patients treated with Siklos® and followed for up to 5 years. The study will focus on the following concerns : occurrence and incidence of malignancies, leg ulcers, male fertility impairment and serious unexpected AEs causally related to Siklos®.
| Condition or disease | Intervention/treatment |
|---|---|
| Sickle Cell Disease | Drug: Hydroxycarbamide |
| Study Type : | Observational |
| Estimated Enrollment : | 2500 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension |
| Actual Study Start Date : | August 21, 2020 |
| Estimated Primary Completion Date : | August 21, 2025 |
| Estimated Study Completion Date : | August 21, 2025 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Sickle cell disease
Drug Information available for:
Hydroxyurea
| Group/Cohort | Intervention/treatment |
|---|---|
| Sickle cell disease patients treated with Siklos |
Drug: Hydroxycarbamide
Patients, aged ≥ 2 years old, with symptomatic SCD, treated with Siklos®.
Other Names:
|
Primary Outcome Measures :
- Occurrence and incidence of the number of malignancies, leg ulcers, male fertility impairment and serious unexpected AEs causally related to Siklos® [ Time Frame: 5 years ]
- Occurrence and incidence of the number of leg ulcers [ Time Frame: 5 years ]
- Occurrence and incidence of male fertility impairment [ Time Frame: 5 years ]
- Occurrence and incidence of serious unexpected AEs causally related to Siklos® [ Time Frame: 5 years ]
Secondary Outcome Measures :
- Mean age of puberty [ Time Frame: 5 years ]Document changes in fertility status in males and females
- Mean number of patients with the use of a contraception, incidence of the use of semen cryopreservation and of semen analysis performed [ Time Frame: 5 years ]Document changes in fertility status in males and females
- Incidence of the use of semen cryopreservation and of semen analysis performed [ Time Frame: 5 years ]Document changes in fertility status in males and females
- Incidence of semen analysis performed [ Time Frame: 5 years ]Document changes in fertility status in males and females
- Management of Siklos® during pregnancy and outcome of pregnancy following exposure at the time of conception or at any time during the pregnancy [ Time Frame: 5 years ]Outcome of pregnancies Following exposure to Siklos® at the time of conception (in participant and participant's partner) or at any time during the pregnancy
- Frequency and reason for temporary or permanent discontinuations of Siklos® [ Time Frame: 5 years ]Potential barriers to the compliance to the prescription of Siklos
- Number of switch and combination with alternative treatment [ Time Frame: 5 years ]
- Measure of quality of life with SF12 questionnaire [ Time Frame: 5 years ]Quality of life for adults SCD patients
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 2 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Investigators will be recruited among physicians experienced in SCD management who are the only ones authorised to initiate Siklos® treatment hence to enrol and to follow up the participants. Investigators who are already participating in ESCORT-HU study will be asked to participate in the extension study.
Patient selection will be based on a systematic sampling technique: during the recruitment period, patients fulfilling the inclusion criteria will be informed by their initiating physician about the ESCORT-HU Extension study and enrolled in case they agree to participate.
Criteria
Inclusion Criteria:
- Male or female patients with symptomatic SCD,
- ≥ 2 years old,
- Treated with Siklos®,
- Having been informed of the study by the investigator and consenting to participate, or whose parents or legal guardians are consenting for their child to participate.
To allow risk evaluation, participants must belong at least to one of the subpopulations defined below:
- Participants previously enrolled in ESCORT-HU who agree to participate in ESCORT-HU Extension study,
-
New participants with any of the following criteria:
- history of HU treatment for more than 5 years or
- prepubescent over 10 years of age for girls and 13 years of age for boys at enrolment, or
- with history of leg ulcer, or
- pregnant women without interruption of Siklos® 3 months before the beginning of the pregnancy or,
- males treated with Siklos® whose partner is pregnant and without discontinuation of Siklos® 3 months before the beginning of the pregnancy.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04707235
Contacts
| Contact: Corinne Duguet, MD | + 33 1 72 69 01 86 | corinne.duguet@addmedica.com | |
| Contact: Laura Thomas-bourgneuf | +33 1 72 69 01 86 | laura.thomas-bourgneuf@addmedica.com |
Locations
Show 79 study locations
Sponsors and Collaborators
ADDMEDICA SASA
International Clinical Trials Association
Investigators
| Study Chair: | Mariane de Montalembert, MD, PhD | Hospital Necker enfants malades | |
| Study Chair: | Frédéric Galactéros, MD, PhD | Henri Mondor University Hospital |
| Responsible Party: | ADDMEDICA SASA |
| ClinicalTrials.gov Identifier: | NCT04707235 |
| Other Study ID Numbers: |
ESCORT-HU Extension |
| First Posted: | January 13, 2021 Key Record Dates |
| Last Update Posted: | March 25, 2022 |
| Last Verified: | March 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn |
Hydroxyurea Antineoplastic Agents Antisickling Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Nucleic Acid Synthesis Inhibitors |